ALSO NOTED: NicOx earns milestone payment; Major pharma company heading to Ohio?; and much more...

> The FDA has given Pfizer and NicOx the go-ahead to begin human testing of its glaucoma treatment candidate, PF-03187207. As part of its agreement with Pfizer, NicOx will a $1.3 million milestone payment. Release

> In a speech, Ohio's Governor Ted Strickland announced that an unnamed pharmaceutical company may be making a $400 million investment the state. Article

> The AARP has stepped into the fight over biologic drugs, throwing its support behind a new bill designed to speed the development and approval of generic versions of these medications. Report

> Research institutions are lining up to protest stalled federal funding for biomedical research. Dr. Edward D. Miller, the head of Johns Hopkins Medical, issued a stern warning to lawmakers that a failure to bump federal research funding at the National Institutes of Health could force a frustrating halt to important research. Report

> A research team at Scripps Research Institute has discovered a simpler, less expensive method for producing synthetic versions of naturally-occurring compounds. By making it possible to produce these compounds less expensively, they say that a number of new drugs could be much more feasible to make. Report

And Finally... Blueberry pigment has been linked to lower rate of colon cancer. Report

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.